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ABSTRACT
The group C of Sry-related high-mobility group
(HMG) box (Sox) transcription factors has three
members in most vertebrates: Sox4, Sox11 and
Sox12. Sox4 and Sox11 have key roles in cardiac,
neuronal and other major developmental processes,
but their molecular roles in many lineages and the
roles of Sox12 remain largely unknown. We show
here that the three genes are co-expressed at high
levels in neuronal and mesenchymal tissues in the
developing mouse, and at variable relative levels in
many other tissues. The three proteins have con-
served remarkable identity through evolution in the
HMG box DNA-binding domain and in the C-terminal
33 residues, and we demonstrate that the latter
residues constitute their transactivation domain
(TAD). Sox11 activates transcription several times
more efficiently than Sox4 and up to one order of
magnitude more efficiently than Sox12, owing to a
more stable a-helical structure of its TAD. This
domain and acidic domains interfere with DNA
binding, Sox11 being most affected and Sox4 least
affected. The proteins are nevertheless capable of
competing with one another in reporter gene
transactivation. We conclude that the three SoxC
proteins have conserved overlapping expression
patterns and molecular properties, and might there-
fore act in concert to fulfill essential roles in vivo.
INTRODUCTION
The family of Sry-related high-mobility group
(HMG) box (Sox) transcription factors counts 20 mem-
bers in most vertebrates (1,2). Sry, which was ﬁrst
discovered, owns its acronym to its critical role as the
sex-determining region on the Y chromosome (3). Its main
feature is a DNA-binding domain similar to that
originally identiﬁed in a HMG of chromatin-associated
nonhistone proteins (4,5). This domain is therefore
referred to as the HMG box. Sox proteins distinguish
themselves in the super-family of HMG box proteins by
sharing 46% or more identity to Sry in the HMG box.
The family is subdivided into eight groups, A–H (6).
Members of the same group are highly similar to each
other within and outside the HMG box, whereas members
of diﬀerent groups share a lower degree of identity in the
HMG box and no signiﬁcant identity outside of this
domain. All Sox genes characterized so far have a speciﬁc
expression pattern and most have critical roles in the
determination of cell fate and diﬀerentiation into speciﬁc
lineages. These lineages include, but are not limited to,
embryonic stem cells, neuronal and glial cells, Sertoli
cells, chondrocytes, endothelial cells and erythroid cells.
Mutations in SOX genes cause severe congenital diseases
in humans, such as XY sex reversal (SRY), campomelic
dysplasia (SOX9), Waardenburg–Hirschsprung syndrome
(SOX8) and anophthalmia–esophageal–genital syndrome
(SOX2). The Sox domain contacts the minor groove of
DNA to AACAAAG, AACAAT and related sequences,
and induces a sharp bend of DNA. It is believed thereby
to allow the proteins to contribute an architectural key
role in the assembly of transcriptional enhancer com-
plexes. It also interacts with various types of transcription
factors to increase its eﬃciency and speciﬁcity of action.
In addition to the HMG box domain, most Sox proteins
feature one or two other functional domains, such as
a transactivation, transrepression or homodimerization
domain, and thus control transcription in several ways.
The SoxC group is composed of a single member in
Drosophila melanogaster (7) and lower animal species, but
has three members in mice, humans and most other
vertebrates: Sox4, Sox11 and Sox12. The three proteins
share a high degree of identity both in the
HMG box domain and in the C-terminal region (8–11).
Sox4 preferentially binds the AACAAAG sequence in
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capable of transactivating a reporter construct harboring
a multimer of this sequence (8). The HMG box is located
in the N-terminal third and the transactivation domain
(TAD) is located within the protein C-terminal third, but
has not been precisely mapped yet. Sox11 has similar
structural and functional properties, but is a more potent
transactivator than Sox4 in transient transfection assays
(9). It also harbors an internal acidic domain that appears
responsible for blocking its ability to bind DNA in
EMSAs and for reducing it in cells (12). Sox12, reported
to as SOX22 in humans, is structurally similar to Sox4 and
Sox11, but its functional properties have not been
reported (13). Altogether, these data are still rudimentary
but already suggest that the three SoxC proteins could
exhibit similar functional properties. A precise delineation
and detailed characterization of their functional domains
and a comparison of their relative activities are needed to
test this possibility.
The expression pattern of each SoxC gene has been
described in several studies, but always independently of
the other group members. Sox4 is expressed in adult
mouse thymus, heart, lung, pancreas and gonads (8), in
embryonic neural progenitors (14,15), pancreatic islets
(16), endocardial cushions (17), terminal chondrocytes
and bone primary spongiosa (18). Sox11 is widely
expressed during organogenesis in the mouse embryo,
and is highly expressed in the human and mouse fetus in
the central and peripheral nervous system, lung, gastro-
intestinal tract, pancreas, spleen, kidneys, gonads, bran-
chial arches and mesenchyme (10,19,20). Similarly,
SOX12 is expressed in neural tissue and mesenchyme in
human embryos, and in brain, lung, heart, liver, spleen,
thymus, pancreas and kidneys in adults (13). Expression
of Sox4 and Sox11 was also shown to be upregulated in
various types of cancers (21–23). These independent
studies strongly suggest major overlap in expression of
the three SoxC genes, but a direct comparison of their
expression patterns is needed not only to conﬁrm this
possibility, but also to assess their relative expression
levels in sites of co-expression.
While no studies have yet been reported on the roles of
Sox12 in vivo, several studies have focused on characteriz-
ing roles for either Sox4 or Sox11 in vivo and have started
to uncover important roles for these two genes in various
developmental, physiological and pathological processes.
Sox4 was shown upon gene inactivation or misexpression
in mice or chickens to have essential roles in heart outﬂow
tract and valve development (17), T and B lymphocyte
diﬀerentiation (24), endocrine islet formation (25), osteo-
blast development (26) and neural and glial cell develop-
ment (15,27,28). Upregulation of SOX4 was shown to
promote survival and proliferation of several types of
cancer cells (22). Sox11 inactivation in the mouse was
shown to cause heart arterial outﬂow tract malformation,
lung hypoplasia, asplenia, cleft lip and palate, open eyelids
and skeletal malformations (20). Only one study so far has
addressed the possibility of functional interaction between
the SoxC genes in vivo. Using RNA interference and
cDNA misexpression in the chicken embryo, this study
has demonstrated essential interaction (likely redundancy)
between Sox4 and Sox11 in the diﬀerentiation of neuronal
progenitors (15). It has shown that Sox4 and Sox11 are
needed for the expression of pan-neuronal genes, includ-
ing the class-III b-tubulin gene Tubb3 (also named Tuj1).
This gene was proposed to be a direct target of the SoxC
proteins by showing that forced expression of Sox4 and
Sox11 in Cos1 cells resulted in upregulation of Tubb3
reporter constructs, and that this eﬀect required cis-acting
elements that the proteins were able to bind to in EMSAs.
Tubb3 is thereby the ﬁrst and still only gene to be
identiﬁed as a potential direct target of SoxC proteins.
Collectively, the expression pattern and functional data
currently available thus strongly suggest that the SoxC
proteins are important transcription factors in many
processes. Further studies are needed to be able to
enumerate the processes that they control, identify their
exact roles and evaluate their degree of possible redun-
dancy or other form of interaction. The present study was
designed to address several of these questions. We have
directly compared the expression patterns of the three
SoxC genes in the mouse and we have analyzed structural
and functional properties of their protein products. We
show that the three genes are co-expressed in many tissues
in the developing mouse, but that their relative expression
levels are highly variable. The three proteins are remark-
ably conserved in the HMG box domain and in the
C-terminus, and the latter domain is their TAD. The three
proteins nevertheless exhibit diﬀerential DNA-binding
and transactivation capabilities, and are thereby able to
functionally interact with each other both positively and
negatively. Our data thus strongly support the notion that
the three genes may work in concert to fulﬁll critical roles
in a multitude of in vivo processes.
MATERIALS AND METHODS
RNA assays
Total RNA was extracted from E12.5 whole mouse
embryos, newborn mouse tissues and cultured cells using
TriZol (Invitrogen, Carlsbad, CA), as recommended by
the manufacturer. Cos1 and MC3T3-E1 cells were
cultured in monolayer under standard conditions in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum (FCS). Mouse primary
neuronal precursors were prepared from E14.5 mouse
embryo cerebrum and cultured in neurospheres as
previously described (29,30). Northern blots were pre-
pared according to a standard protocol. Transcript sizes
were estimated by comparison with a ladder of DNA
markers (Invitrogen). The Sox4 probe was a BglII/SmaI
634-bp fragment of the coding sequence (positions 925–
1558 in the NM_009238 cDNA sequence) (31). The Sox11
probe was a PstI/XhoI 591-bp fragment of the coding
sequence (positions 611–1198 in the NM_009234 cDNA
sequence). The Sox12 probe was a 685-bp fragment of the
30 untranslated region (positions 1585–2270 in the
NM_011438 cDNA sequence). In situ hybridization was
carried out on mouse embryo sections with [
35S]-rUTP-
labeled RNA probes (32). Cell nuclei were counterstained
with the Hoechst 33258 DNA-binding dye. RNA probe
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using a red ﬁlter and blue ﬂuorescence. Staining of
adjacent sections with hematoxylin and eosin was
performed according to a standard procedure.
Protein sequence analysis
Sequences of SoxC proteins from various vertebrate
species were downloaded from the NCBI website (http://
www.ncbi.nlm.nih.gov). Accession numbers were as fol-
lows: Homo sapiens (human) SOX4: NP003098, SOX11:
NP003099, SOX12: NM006943; Mus musculus (mouse)
Sox4: NP033264, Sox11: NP033260, Sox12: NM 011438;
Bos taurus (cow) Sox4: NP001071596, Sox11: NP 990518;
Monodelphis domestica (opossum) Sox4: hmm10497,
Sox11: XP001372169, Sox12: XP001365568; Gallus gallus
(chicken) Sox4: NP989815, Sox11: NP990518; Xenopus
tropicalis (clawed frog) Sox4: NP001039084, Sox11:
NP001008053; Takifugu rubripes (puﬀerﬁsh) Sox4:
AAQ18501, Sox11: AAQ18502, Sox12: AAQ18530 and
Canis familiaris (dog) Sox12: XP542944. These sequences
were aligned with ClustalX software (http://www-
igbmc.u-strasbg.fr/BioInfo/ClustalX) (33) using default
settings. Secondary structure predictions were obtained
using the MLRC webware tool (http://pbil.ibcp.fr) (34).
Expression plasmids
Mouse SoxC and Brn2 expression plasmids were gener-
ated essentially as previously described for human SOX9
and mouse Sox6 (35,36). Brieﬂy, the full-length coding
sequence of each protein was ampliﬁed by PCR using
mouse 129xB6 genomic DNA. The PCR products were
cloned in the pCR4-TOPO vector (Invitrogen) and
veriﬁed by DNA sequencing. They were then cloned
in the pcDNA3.1+ mammalian expression plasmid
(Invitrogen) with or without an in-frame N-terminal
FLAG epitope sequence. SoxC mutant sequences were
generated by PCR using appropriate primers. Plasmids
encoding GAL4/SoxC fusion proteins were generated by
cloning SoxC segments downstream and in frame with the
GAL4 DNA-binding domain in the pBIND plasmid
(Promega, Madison, WI).
Reporter plasmids
The 6FXO-p89Luc reporter was constructed by cloning
six tandem copies of the FXO sequence (37) in the
previously described p89Luc plasmid (38). This plasmid
featured a minimum (89bp) Col2a1 promoter driving the
ﬁreﬂy luciferase gene. Tandem copies of the FXO
sequence were generated by ligating oligonucleotides
corresponding to the FXO sequence and ﬂanked with
BamHI and BglII restriction sites at the 50 and 30 end,
respectively, with each other. Multimers were cloned in
p89Luc and veriﬁed by sequencing. The 4x48-p89Luc
reporter was as described (38). The 2HMG-p89Luc
reporter was constructed by multimerizing the 2HMG
probe and as described 6FXO-p89Luc (36). The Tubb3-
pLuc reporter was constructed by cloning a PCR-
ampliﬁed  215/+54 mouse Tubb3 promoter into the
promoter-less pA3luc plasmid (38). The GAL4 reporter
pG5Luc plasmid contained ﬁve copies of the GAL4
binding site upstream of a minimal promoter driving
the ﬁreﬂy luciferase gene (Promega). The pSV2-lacZ
plasmid, in which the SV40 promoter and enhancer
drove lacZ expression, was used to determine transfection
eﬃciency (39).
Transient transfection
Cos1 and MC3T3-E1 cells were plated at a density of
3.10
5 cells/10cm
2 dish in 2ml DMEM supplemented with
10% FCS and antibiotics. Transfection mixtures were
added to the culture medium 3–6h later. These mixtures
consisted of 1mg total plasmid, 3ml FuGENE6 (Roche,
Indianapolis, IN) and 100ml DMEM. Neurospheres were
transfected at the passage 2–6 by electroporation with the
Amaxa system according to the manufacturer’s instruc-
tions for mouse neural stem cells (Amaxa, Gaithersburg,
MD). Unless otherwise indicated, the plasmid mixtures of
all transfections consisted of 300ng pSV2-lacZ control
plasmid, 600ng luciferase reporter plasmid and 200ng
expression plasmid. Expression plasmids contained var-
ious proportions of empty pcDNA3.1+ vector and Sox or
Brn2 expression vectors, as indicated in ﬁgures. Cells were
harvested 24h after transfection and whole-cell extracts
were made in 150ml buﬀer containing 14mM HEPES (pH
7.9), 1.5mM MgCl2, 6.0mM KCl, 0.44M NaCl, 0.08mM
EDTA, 2.3mM DTT, 0.5mM PMSF, 10mg/ml leupeptin,
10mg/ml pepstatin A, 4.6% Ipegal and 10% glycerol.
Luciferase and b-galactosidase activities were assayed in
these extracts using the Dual-Light combined reporter
gene assay system (Applied Biosystems, Foster City, CA)
and a Wallac Victor 1420 microplate reader (Perkin-Elmer,
Waltham, MS). Reporter gene activities are presented
in ﬁgures in relative luciferase units (RLU). They were
obtained by multiplying luciferase activity units by 10
3
and dividing them by b-galactosidase activity units.
Figures show averages with standard deviation of three
independent assays in one representative experiment.
Westernblot analysis
Western blot of whole-cell extracts (prepared as described
earlier) were performed according to a standard protocol.
Dual-Color standards were used as protein Mr markers
(Amersham, Piscataway, NJ). Proteins harboring a FLAG
epitope were detected using a mouse monoclonal anti-
FLAG M2-peroxidase HRP antibody (Sigma, St. Louis,
MO, A8592). As indicated in ﬁgure legends, SoxC proteins
were also detected using rabbit polyclonal antibodies
directed against a 14-amino-acid sequence fully conserved
in all SoxC HMG box domains (Sigma, S8068; sold as
Sox11 antibody), and goat HRP-linked anti-rabbit IgG
secondary antibodies. GAL4/SoxC fusion proteins were
detected using a mouse monoclonal HRP conjugate
antibody against the GAL4 DNA-binding domain
(Santa Cruz, Santa Cruz, CA, sc-510). Antibody hybridi-
zation signals were detected using the ECL Western
Blotting Analysis System (Amersham).
EMSA
Double-stranded oligonucleotide probes were synthe-
sized with the addition of three Gs in 50 overhang on
Nucleic Acids Research, 2008, Vol. 36, No. 9 3103each strand and they were labeled with a-
32P-dCTP by
Klenow ﬁlling-in. Assay mixtures were made in DNA-
binding buﬀer (20mM HEPES, pH 7.9, 40mM KCl,
0.5mM EDTA, 0.5mM DTT, 1mM PMSF, 10%
glycerol) with 10fmol labeled probe, 1–3ml whole-cell
extracts and 0.25–1mg poly(dG-dC) poly(dG-dC). They
were incubated for 30min at 308C followed by electro-
phoresis in 4% polyacrylamide native gels in 0.5  TGE
buﬀer (50mM Tris, 0.4M glycine, 4.5mM EDTA, pH
8.0). Dried gels were exposed to X-ray ﬁlms for 1h to
overnight.
RESULTS
Overlappingexpression ofthe SoxCgenes invivo
We compared the expression patterns of the three SoxC
genes in the mouse by northern blot and RNA in situ
hybridization. To estimate the relative expression levels
of the genes, we used RNA probes that exhibited
similar annealing temperatures and labeling speciﬁcities.
Northern blot of total RNA from whole embryos
demonstrated that the probes recognized speciﬁc tran-
scripts (Figure 1A). Sox4 was expressed predominantly as
a  5kb RNA, Sox11 as a  7kb RNA and Sox12 as
 3 and 3.5kb RNAs. The comparison of tissue
RNAs from 2-day-old mice showed that all three genes
were expressed at a very high and similar level in the brain
(Figure 1B). Sox4 and Sox12 were also expressed at a high
level in a distinct set of organs, including the heart and the
lung, and at a low or insigniﬁcant level in most other
tissues, such as the liver, pancreas and small intestine.
Sox11, in contrast, was hardly detected in nonneuronal
tissues at that age. Hybridization of RNA from cultured
cells showed high expression of the three genes in neuronal
precursor cells isolated from mouse embryo cerebrum and
maintained in primary culture as neurospheres (40,41).
Sox4 and Sox11 but not Sox12 were also expressed in
kidney Cos1 ﬁbroblasts and in mesenchymal preosteo-
blastic MC3T3-E1 cells (42).
In situ hybridization of RNA in mouse embryo sections
from E10.5 to E18.5 showed co-expression of the three
SoxC genes in most areas of the central and peripheral
nervous system, including the brain, neural tube, retina,
olfactory epithelium, cochlear epithelium and dorsal root
ganglia (Figure 1C and D; data not shown). The three
genes were also co-expressed in the mesenchyme of many
presumptive and developing organs, such as skeletogenic
primordia and genital tubercle, and in both the epithelium
and the mesenchyme of the developing lung, kidney and
midgut. Several sites of diﬀerential expression were
observed. For instance, the eyelid primordium and palatal
shelf mesenchyme expressed Sox11 and Sox12, but not
Sox4; the developing heart endocardial cushions expressed
Sox4 and Sox12, but not Sox11; and the developing teeth,
spleen, thymus and hair follicles predominantly expressed
Sox4 (Figure 1C–E).
The three SoxC genes are thus co-expressed at high
levels in neuronal and mesenchymal tissues and cells
in vivo and in vitro, and at distinct, variable levels in many
other tissues in vivo. These results prompted us to
determine to which extent the three SoxC proteins share
molecular properties, a prerequisite to understand their
mode of possible functional interaction in sites of
co-expression.
The SoxC proteins share ahighly conserved C-terminus
We downloaded 18 SoxC protein sequences from seven
vertebrate species, from ﬁsh to human, and aligned them
with ClustalX software to identify evolutionary conserva-
tion (Figure 2A). The results were clear-cut: the three
SoxC proteins share the three N-terminal residues, most
residues constituting and located immediately upstream of
the HMG box domain, most of the 33 C-terminal residues
and a few upstream residues, but no other stretch of
contiguous residues. Orthologous proteins, nonetheless,
share signiﬁcant conservation in other regions, such as
acidic and serine-rich domains (Supplementary Figure 1).
Close inspection of the HMG box domains revealed 84%
identity and 95% similarity between all SoxC proteins
(Figure 2B), but only 45–67% identity to Sry and the
other Sox proteins (unpublished results). All SoxC
proteins share 67% identity and 94% similarity in the
C-terminal 33 residues, hereafter referred to as the C33
domain. This domain is thus almost as highly conserved as
the HMG box domain. It has no signiﬁcant identity,
however, with sequences in other proteins (unpublished
results). Interestingly, the HMG box and C33 domains are
more highly conserved among Sox4 orthologues and
among Sox11 orthologues than among Sox12 ortho-
logues. They are also more highly conserved between
Sox4 and Sox11 orthologues than between these two types
of orthologues and the Sox12 orthologues. Almost half of
the C33 domain sequence is constituted of proline, serine,
and acidic residues, as typically seen in TADs (Figure 2C).
Protein secondary structure models predict that 20
residues in the Sox11 C33 domain (C23-C3) form a
noninterrupted a-helix. A similar helix is predicted to
form in Sox4 and Sox12. However, the Sox4 helix is
predicted to be interrupted in the middle of its sequence
by three randomly coiled residues (C16-C14), and to have
the last two residues (C4-C3) in extended conformation
rather than in helical conformation. The Sox12 helix is
predicted to be even more discontinuous, with seven
randomly coiled residues (C15-C7) in the middle of its
sequence. The vertebrate SoxC proteins have thus tightly
conserved both the HMG box domain and the C33
domain. Each orthologue has nevertheless evolved to
exhibit speciﬁc features, which suggest important, protein-
speciﬁc functions.
The SoxC proteins transactivate withdifferent efficiencies
We compared the transactivation potential of the mouse
SoxC proteins by transiently transfecting Cos1 cells with
expression plasmids for these proteins and with several
reporter plasmids (Figure 3A). Three reporters featured a
minimal 89bp Col2a1 promoter (p89) driving the ﬁreﬂy
luciferase gene (38). This promoter contains a
TATA box and GC-rich elements, but no other binding
sites for known transcription factors, and it was pre-
viously shown to be virtually inactive in transient
3104 Nucleic Acids Research, 2008, Vol. 36, No. 9Figure 1. Comparison of the SoxC gene expression pattern in the mouse. (A) Northern blots of total RNA from E12.5 mouse embryos hybridized
with Sox4, Sox11 and Sox12 probes, as indicated. A picture of the RNA stained with ethidium bromide before blotting is shown in the left lane. The
migration level and size of DNA markers run on the same gel are indicated on the right. The three probes had the same labeling speciﬁcity and the
three blots were exposed for the length of time to allow direct comparison of RNA levels. (B) Northern blots showing the relative expression levels of
the SoxC RNAs in various tissues of 2-day-old mice and in cultured cells. WE, whole embryo at E12.5; Br, brain; He, heart; Lu, lung; Li, liver; Pa,
pancreas; SI, small intestine; Nph, mouse embryo primary neurospheres; Cos1, monkey kidney ﬁbroblastic cell line; MC3T3, preosteoblastic MC3T3-
E1 cell line. The three probes had the same labeling speciﬁcity and the blots in each of the three sub-panels were exposed for the same length of time
to allow direct comparison of RNA levels. The size of the Sox11 RNA in monkey Cos1 cells was  5kb, instead of  7kb in mouse tissues and cells
(unpublished results). (C) RNA in situ hybridization of adjacent mid-sagittal sections of E12.5 mouse embryos with Sox4, Sox11 and Sox12 probes.
The left-side section was stained with hematoxylin and eosin (H&E). CM, craniofacial (skeletogenic) mesenchyme; CNS, central nervous system;
GM, genital tubercle mesenchyme; H, heart; TO, tongue; VM, vertebral column (skeletogenic) mesenchyme. (D) RNA in situ hybridization of
adjacent coronal sections of mouse embryo heads at E14.5 and E18.5 with SoxC probes. EL, eyelid mesenchyme; J, presumptive jaw mesenchyme;
M, mesenchyme; OE, olfactory epithelium; PS, palatal shelves; R, retina; S, skin primordium TO, tongue; TE, teeth. (E) RNA in situ hybridization
of various developing organs in E14.5 to E18.5 embryos with SoxC probes, as indicated. Ep, epithelium; HF, hair follicle; Mg, midgut;
Ms, mesenchyme; Sp, spleen; Th, thymus.
Nucleic Acids Research, 2008, Vol. 36, No. 9 3105Figure 2. Comparison of the SoxC protein sequences in vertebrates. (A) ClustalX alignment of the Sox4, Sox11 and Sox12 protein sequences in various
vertebrate species. Symbols underneath the alignments denote fully conserved amino acid residues (asterisk), conservative changes (colon) and semi-
conservative changes (dot). Boxes highlight the highly conserved HMG box domain and the C-terminal domain (from residues C49 and C33 to C1), and
as well as partially conserved acidic, serine-rich and glycine-rich domains identiﬁed by the ScanProsite tool. (B) Venn diagrams depicting the degrees of
identity and similarity (the latter in parentheses) of SoxC orthologues in the HMG box and C33 domains. Each of the Sox4, Sox11 and Sox12 subgroups
of orthologues is schematized as a circle. Numbers indicate the percentage of conservation between orthologues in the same subgroup (nonoverlapping
circle areas) and between orthologues in diﬀerent groups (overlapping circle areas). (C) ClustalX alignment of SoxC C33 domain sequences. Boxes with a
continuous line highlight residues in a-helical conformation and the box with a dotted line highlights residues in extended conformation.
3106 Nucleic Acids Research, 2008, Vol. 36, No. 9transfection of any cell type (36). The 6FXO-p89Luc
reporter harbored six tandem copies of a minimum Fgf4
enhancer directly upstream of the p89 promoter. This
enhancer is a direct target of Sox2 and the POU domain
protein Oct3 in embryonic stem cells (37). It contains a
binding site for Sox proteins immediately adjacent to a
POU domain protein-binding site, and it is synergistically
activated by several types of Sox and POU proteins,
including Sox4, Sox11 and the neuronal cell-speciﬁc POU
domain protein Brn2 (9,37). The 2HMG-p89Luc reporter
harbored two tandem copies of a CD3" minimal enhancer
(43). This enhancer was originally shown to contain a
binding site for Sry and has been frequently used as a
reference to evaluate and compare the DNA-binding and
transactivation properties of various members of the Sox
family. The 4x48-p89Luc reporter featured four tandem
copies of a 48bp Col2a1 intron-1 sequence (35,38). This
sequence is a cartilage-speciﬁc enhancer directly targeted
by the SoxE protein Sox9 and SoxD proteins L-Sox5 and
Sox6 in chondrocytes. A fourth reporter featured the
mouse Tubb3 proximal promoter from –215 to +54
directly driving the ﬁreﬂy luciferase gene. As described in
the Introduction section, this promoter segment contains
three Sox-like binding sites needed for activity and is
believed to be directly targeted by Sox4 and Sox11 (15).
Using the 6FXO-p89Luc reporter ﬁrst, we found, as
previously reported (9), that Sox11 was a more potent
transactivator than Sox4 (Figure 3B). Sox12 was also able
to transactivate this reporter but less eﬃciently.
Interestingly, although Sox11 was a better transactivator,
we reproducibly observed that less Sox4 and Sox12
protein was needed than Sox11 protein to reach a plateau
of maximum transactivation. The same relative diﬀerences
were observed when the proteins were allowed to synergize
with Brn2 (Figure 3C). They were also observed when the
proteins harbored an N-terminal FLAG epitope
(Figure 3D), and we therefore pursued our studies with
FLAG-tagged proteins. The same relative diﬀerences were
also observed using the 2HMG-p89Luc and 4x48-p89Luc
reporters (Figure 3E). Of note, the SoxC proteins
activated 6FXO-p89Luc and 2HMG-p89Luc as eﬃciently
as Sox9 did, but activated 4x48-p89Luc much less
eﬃciently. This result is consistent with the notion that
the SoxC proteins are functionally more closely related to
each other than to other Sox proteins. Finally, the same
relative diﬀerences were also observed when the 6FXO-
p89Luc and Tubb3-pLuc reporters were transfected into
Cos1, MC3T3-E1 and neuronal precursor cells
(Figure 3F). Together, these data demonstrate for the
ﬁrst time that Sox12 is a transactivator and that it is
several fold less potent than Sox4, and up to an order of
magnitude less potent than Sox11.
The SoxCC33 domain is neededfortransactivation
The TAD of Sox4 and Sox11 was previously shown to be
located in the protein 140- and 123-residue-long
C-terminal third, respectively, but it was not precisely
mapped (9,12). We postulated that it could correspond to
the most conserved region of the C-terminus. To test
whether this region is needed for transactivation, we
constructed expression plasmids for SoxC proteins lacking
the C-terminal third (Sox4-C140 and Sox11-C123), the
C-terminal 52 residues (SoxC-C52), the C-terminal 33
residues (SoxC-C33) or the entire C-terminal third except
the last 52 residues (Sox4-C140/53 and Sox11-C123/53)
(Figure 4A). The SoxC-C33 and SoxC-C52 proteins were
virtually unable to transactivate 6FXO-p89Luc in tran-
sient transfection of Cos1 cells (Figure 4B). Sox4-C140
and Sox11-C123 were also unable to transactivate, as
expected, but Sox4-C140/53 and Sox11-C123/53 could
transactivate as eﬃciently as the full-length proteins
(Figure 4C). Interestingly, deletion of the C33 domain
completely blocked the ability of the SoxC proteins to
cooperate with Brn2 (Figure 4D). These data thus
demonstrated that the SoxC C33 domain is absolutely
needed for transactivation, and that upstream sequences
in the C-terminal third are not.
The SoxCC33 domain is sufficient fortransactivation
To determine which segment in the C-terminus of the
SoxC proteins is suﬃcient for transactivation, we con-
structed plasmids encoding the GAL4 DNA-binding
domain fused to the Sox4 or Sox11C-terminal third
(GAL4/C140[4] or GAL4/C140[11]), the SoxC C52
domain (for Sox4: GAL4/C52[4]) or the C33 domain
(for Sox4: GAL4/C33[4]), and we tested the ability of
these fusion proteins to transactivate pG5Luc, a reporter
gene featuring ﬁve GAL4 binding sites (Figure 5A).
GAL4/C140[4] and GAL4/C123[11] were able to tran-
sactivate the reporter, as previously shown (9,12).
Interestingly, GAL4/C123[11] was more potent than
Figure 2. Continued.
Nucleic Acids Research, 2008, Vol. 36, No. 9 3107Figure 3. Comparison of the transactivation activity of the mouse SoxC proteins. (A) Schematic of Sox reporter genes. Each reporter features
a minimal Col2a1 promoter (p89) driving the ﬁreﬂy luciferase gene. The FXO, HMG and 48bp Col2a1 intron-1 fragment sequences were cloned as
6, 2 or 4 tandem copies, respectively, directly upstream of the promoter. The Sox recognition sites are underlined with a continuous line. The POU-
domain recognition site and a Sox-like site in the FXO sequence are shown with a dotted and a double line, respectively. (B) Comparison of the
ability of the SoxC proteins to transactivate 6FXO-p89Luc. The 6FXO-p89Luc was transfected into Cos1 cells with 0, 10, 30, 100 or 300ng of either
SoxC expression plasmid, supplemented with empty expression plasmid up to 300ng. Reporter activities are plotted against the amount of SoxC
expression plasmid. The western blot illustrates the amount of SoxC protein present in the cells at the end of the experiment. The amount of extract
loaded on the gel for each condition was normalized for transfection eﬃciency. An anti-FLAG antibody was used to detect the proteins. This blot
demonstrates that all SoxC proteins were produced at a similar level for each expression plasmid amount, and therefore that the diﬀerences seen
between the SoxC proteins in transactivation eﬃciency are due to diﬀerences in the intrinsic properties of the proteins rather than to diﬀerences in
their relative amounts. The Mr of protein standards is indicated on the left of the blot. Note that each SoxC protein exhibits an apparent Mr (Sox4,
69k; Sox11, 68k; Sox12, 45k) slightly larger than predicted (Sox4, 45k; Sox11, 43k; Sox12, 34k). (C) Comparison of the ability of the three SoxC
proteins to transactivate the 6FXO-p89Luc reporter in synergy with Brn2. Cos1 cells were transfected with the reporters and 100ng Brn2 and 100ng
of SoxC expression plasmid. Note that the scale of the graph is logarithmic. Reporter activities are indicated. (D) Comparison of the transactivation
eﬃciency of SoxC proteins with and without an N-terminal FLAG epitope. Cos1 cells were transfected with 200ng expression plasmid for SoxC
proteins with (F4, F11 and F12) or without (4, 11 or 12) the FLAG epitope fused at the N-terminus. All SoxC proteins were detected by western blot
using a SoxC antibody. (E) Comparison of the ability of the three SoxC proteins and Sox9 to transactivate the 6FXO-p89Luc, 2HMG-p89Luc and
4x48-p89Luc reporters. Cos1 cells were transfected with the reporters and 200ng of Sox expression plasmid. SoxC proteins were detected with anti-
FLAG antibody. Note that it is important to consider the relative amounts of protein expressed in each condition to properly interpret data.
(F) Comparison of the ability of the three SoxC proteins to transactivate the 6FXO-p89Luc and Tubb3-pLuc reporters in Cos1 cells, MC3T3-E1 cells
and neurospheres. Cells were co-transfected with the reporters and with 200ng (Cos1 and MC3T3-E1) or 600ng (neurospheres) of SoxC expression
plasmid.
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Figure 4. The SoxC C33 domain is required for transactivation. (A) Schematic of SoxC proteins truncated in the C-terminus. The name of each
protein is indicated on the left of the rectangle representing it. Numbers designate the ﬁrst and last protein residues and relevant domain boundaries.
A thin line denotes internal deletions. (B) Eﬀect of deleting the C52 or C33 region on the ability of SoxC proteins to transactivate 6FXO-p89Luc.
Cos1 cells were transfected with 200ng expression plasmid encoding a full-length SoxC protein (FL) or a SoxC protein lacking the C52 ( 52) or C33
( 33) domain. Reporter activities are indicated. SoxC proteins were detected by western blot with anti-FLAG antibody. Note partial degradation of
the Sox11-C33 and Sox11-C52 proteins. (C) Eﬀect of deleting the SoxC C-terminal third or an internal region on the ability of Sox4 and Sox11 to
transactivate 6FXO-p89Luc. Cos1 cells were transfected with 200ng expression plasmid encoding a full-length SoxC protein (FL), a SoxC protein
lacking the C-terminal third ( 140 and  123) or a Sox protein lacking an internal segment ( 140/53 and  123/53). SoxC proteins were detected by
western blot with anti-FLAG antibody. (D) Eﬀect of deleting the C33 domain on the ability of SoxC proteins to synergize with Brn2 in
transactivating 6FXO-p89Luc. Cos1 cells were transfected with 100ng expression plasmid encoding Brn2 and 100ng of expression plasmid encoding
a full-length (FL) SoxC protein or a SoxC protein lacking C33 ( C33). The western blot with a FLAG antibody shows the amount of Brn2 protein
(arrow) made in each culture and some of the SoxC proteins. The western blot with the SoxC antibody shows the relative amounts of SoxC proteins
made in each culture. These proteins appear as doublet, an electrophoresis artifact.
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as potent as GAL4/C140[4], and GAL4/C52[11] and
GAL4/C33[11] were as potent as GAL4/C123[11].
GAL4/C52[12] and GAL4/C33[12] were able to transacti-
vate, but were less potent than the GAL4/Sox4 and
GAL4/Sox11 fusion proteins. These data thus indicate
that the C33 domain is suﬃcient for transactivation, and
they suggest that sequence diﬀerences between the three
proteins in this domain contribute, at least in part, to the
diﬀerences in transactivation eﬃciency of the full-length
proteins.
To test the latter possibility, we exchanged the SoxC
C52 domains (Figure 5B). In doing so, we introduced a
serine and a threonine residue (encoded by the ScaI
restriction enzyme site) between the C53 and C52 residues,
but veriﬁed that swapping the C52 domain of either
protein with itself (i.e. inserting two new amino acids)
did no signiﬁcantly aﬀect the activity of the proteins.
Swapping the Sox4 C-terminus with C52[11] resulted in
increasing the activity of Sox4, whereas swapping it with
C52[12] had no eﬀect. Swapping the Sox11 C-terminus
with C52[4] or C52[12] decreased the activity of Sox11,
and swapping the Sox12 C-terminus for C52[4] or C52[11]
resulted in increasing the activity of Sox12. We concluded
that the C33 domain is the SoxC TAD, and that strength
diﬀerences between the three SoxC domains explain, at
least in part, diﬀerences in strength between the full-length
proteins.
The SoxC proteins bind DNA with different
efficiencies in vitro
We next compared the DNA-binding properties of the
three SoxC proteins. We used several probes (Figure 6A).
FXO corresponded to the Fgf4 DNA element described
earlier. FXO+ was an FXO variant, in which the Sox
binding site was optimized for SoxC proteins by changing
ﬂanking nucleotides according to a previous report (44).
2HMG featured two tandem copies of the HMG sequence
described earlier. As a source of protein, we used crude
extracts from Cos1 cells transiently transfected with
expression plasmids for Sox proteins harboring an
N-terminal FLAG epitope (Figure 6B). We found that
Sox4 bound all probes as eﬃciently as Sox6 and Sox9
(Figure 6C). Each protein bound FXO+ slightly more
eﬃciently than the other two probes. We therefore
conducted further assays with FXO+. Binding of Sox11
to this probe was hardly if ever detectable (Figure 6D).
Sox12 binding was readily detectable, but always less
eﬃcient than Sox4 binding. Sox4 formed a ternary
complex with Brn2 and DNA, and Sox12 did too, but
even in this condition, Sox11 did not bind DNA. The
same results were obtained using probes corresponding
to SoxC binding sites in the Tubb3 promoter (unpublished
results).
Based on the fact that the HMG box domains of the
three SoxC proteins are almost identical, we postulated
that speciﬁc regions outside this domain were responsible
for controlling DNA binding. The deletion of the
N-terminal region, up to six residues upstream of the
HMG box, blocked the ability of each protein to bind
DNA (unpublished results). Deletion of the C52 or C140
domain did not signiﬁcantly aﬀect the ability of Sox4 to
bind DNA (Figure 6E). In contrast, the deletion of the
C52 domain was suﬃcient to allow Sox11 to bind DNA
and to increase the ability of Sox12 to bind DNA. Larger
deletions in the C-terminal half further increased the
Figure 5. The SoxC C33 domain is suﬃcient for transactivation.
(A) Schematic of GAL4-SoxC fusion proteins and transactivation of
pG5Luc by these proteins. Cos1 cells were transfected with 100ng GAL4/
SoxC expression plasmid. Reporter activities are presented in comparison
with the amount of GAL4/SoxC fusion proteins present in each culture at
the end of the experiment and detected with anti-GAL4 antibody. (B)
Schematic of Sox4 proteins with swapped SoxC C52 regions and
transactivation of 6FXO-p89Luc by these swapped SoxC proteins. The
swapped Sox11 and Sox12 proteins were made as shown for Sox4. Cos1
cells were transfected with 100ng swapped SoxC expression plasmid.
SoxC proteins were detected with an anti-FLAG antibody.
3110 Nucleic Acids Research, 2008, Vol. 36, No. 9Figure 6. Comparison of the DNA-binding eﬃciency of the SoxC proteins. (A) Sequences of FXO, FXO+ and 2HMG EMSA probes. Sox, Sox-like
and POU domain protein binding sites are underlined. (B) Western blot with anti-FLAG antibody demonstrating the relative amounts of proteins
used in EMSA in (C) and (D). (C) EMSA of Sox4, Sox6 and Sox9 with the FXO, FXO+ and 2HMG probes. The Sox protein/DNA complexes are
identiﬁed with arrows. (D) EMSA of SoxC proteins with FXO+ in the presence (+) or absence ( ) of Brn2. Speciﬁc protein/DNA complexes are
identiﬁed with arrows. Note that the Sox4/DNA complex migrates with the same mobility as a less abundant complex present in all samples and that
the free probe ran oﬀ the right part of the gel. (E) Eﬀect of deleting an increasing segment of the SoxC C-terminus on the ability of the proteins to
bind DNA. SoxC proteins were made in Cos1 cells as schematized and used in EMSA with the FXO+ probe. The SoxC/DNA complexes are
identiﬁed in the EMSA with asterisks and a nonspeciﬁc complex with an open triangle. A western blot (WB) hybridized with an anti-FLAG antibody
shows the relative amounts of the various proteins. (F) Eﬀect of deleting the acidic regions of Sox11 and Sox12 on the protein’s ability to bind DNA
and transactivate. Cos1 cells were transfected with 200ng of expression plasmid encoding full-length or deletion mutant proteins, as schematized, and
with the 6FXO-p89Luc reporter and control plasmids. SoxC proteins were tested in EMSA with the FXO+ probe and detected in western blot with
an anti-FLAG antibody.
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the main acidic region (AR1) of Sox11 resulted in
increasing about 2-fold the ability of the protein to bind
DNA in EMSA and to transactivate 6FXO-p89Luc in
cultured cells, as previously reported (12). Deletion of a
smaller acidic region (AR2) had a similar, but milder
eﬀect, and deletion of both regions was as eﬀective as
deleting AR1 only. Similar eﬀects were observed upon
deleting similar acidic regions in Sox12. The data therefore
indicated that several domains in Sox11 and Sox12,
including the acidic regions and TAD, interfere with
the protein’s ability to bind DNA in vitro and possibly
also in cells.
The SoxCproteins functionally interferewith eachother
Finally, we asked whether the SoxC proteins are capable
of functionally interacting with each other when
co-expressed in the same cells. We did so by testing the
eﬀect of co-transfecting full-length SoxC proteins with
SoxC proteins truncated in the C-terminus. We
observed that the activity of either full-length protein
was dramatically inhibited by expressing equivalent
amounts of any of the SoxC proteins lacking the C33
domain (Figure 7A). Similar results were obtained in
the presence (Figure 7A) and absence of Brn2 (unpub-
lished results) and with larger C-terminal truncations in
Sox11 (Figure 7B). Furthermore, each SoxC protein
lacking the C33 domain was also able to interfere with
the activity of the Tubb3 reporter, supporting the notion
that these mutant proteins were able to interfere with the
activity of the endogenous SoxC proteins (Figure 7C).
These data thus strongly suggest that, when co-expressed
in vivo, the SoxC proteins compete with each other to
bind and activate their target genes and that gene
mutations or protein modiﬁcations that would either
delete or inactivate the TAD of a SoxC protein could
not only block the activity of this protein, but could
also aﬀect the activity of all co-expressed, intact SoxC
proteins.
DISCUSSION
Previous studies have started to reveal critical roles for
either or both Sox4 and Sox11 in developmental,
physiological and possibly pathological processes, but
the extent of their individual and interacting roles in vivo,
their exact molecular roles, and their modes of regulation
remain poorly known. There also remains virtually
nothing known about the third member of SoxC group,
Sox12. This study has provided several pieces of evidence
that strongly support the notion that the three SoxC
proteins are likely to functionally interact with each other
in many lineages and thereby to fulﬁll a multitude of
critical roles in developmental, physiological and possibly
pathological processes. We have shown that the three
genes are co-expressed in a number of important cell
lineages. Their tight conservation in the HMG box DNA-
binding domain and in the TAD allows them to compete
for DNA binding and transactivation. However, sequence
variations between the three proteins in the TAD and in
other domains are responsible for diﬀerential eﬃciencies
in DNA-binding and transactivation, such that each
protein may have speciﬁc activities and modes of
regulation, and may thereby interact either positively or
negatively with its relatives.
Several research groups previously analyzed the expres-
sion pattern of the SoxC genes, but each group analyzed
only one gene at a time, and often used a diﬀerent species,
developmental stages, probe or method than the other
groups (8,10,13,18,20). The results of these studies there-
fore did not indicate how the three genes compare to each
other in their pattern and level of expression. To obtain
such information, which is important to determine
whether the genes may functionally interact, we prepared
embryos sections and northern blots with various mouse
tissues and cultured cells, and hybridized them with SoxC
probes that had similar length, nucleotide composition
and labeling eﬃciencies. Both approaches revealed
co-expression of the three genes in many tissues.
Neuronal and mesenchymal tissues expressed the three
genes at similarly high levels, whereas many other tissues,
such as the heart, thymus, spleen and hair follicles,
expressed the three genes at generally lower and variable
relative levels. These expression data thus constitute a ﬁrst
piece of evidence that the three SoxC genes might
functionally interact in many processes. They imply that
the three genes may have conserved a high degree of
identity in critical promoter elements or in other
regulatory regions that specify co-expression in multiple
tissues. A combination of bioinformatics and experimental
approaches will be needed to test this possibility and
uncover the shared and distinct modes of transcriptional
regulation of the three genes.
Functional studies in vivo have already revealed
important roles for Sox4 and Sox11 in several develop-
mental processes, but one can predict that the roles of the
genes will only be fully revealed upon inactivation of
the entire SoxC group. Only in neuronal cells has the
consequence of inactivating two genes (Sox4 and Sox11)
been assessed so far (15). This study, however, did not
demonstrate whether redundancy exists between the two
genes and did not assess the role of Sox12. Co-expression
of group members was shown for several other Sox
groups, including the B, D, E and F groups, and was
demonstrated to result in gene redundancy in most cases
(2). The SoxB2 genes (Sox14 and Sox21), however, were
shown to counteract the action of the SoxB1 genes (Sox1,
Sox2 and Sox3) in neuronal cells (45). Counteraction was
explained by the fact that the SoxB1 and SoxB2 proteins
have almost identical HMG box DNA-binding domains,
but the SoxB1 proteins have a TAD, whereas the SoxB2
proteins have a transrepression domain. Since Sox4 and
Sox11 were previously shown to have a TAD, but Sox12
was not previously characterized, these data prompted us
to further characterize and compare the functional
properties of the three SoxC proteins.
The alignment of SoxC protein sequences from multiple
species revealed that all proteins are 94–100% similar in
two domains: the HMG box and the C-terminal 33-residue
segment. The former domain has long been known to
mediate DNA binding, but the function of the C-terminal
3112 Nucleic Acids Research, 2008, Vol. 36, No. 9segment had not been previously demonstrated. Given that
the TAD of Sox4 and Sox11 was previously located within
the C-terminal third of the proteins, but not precisely
mapped, we postulated that the most conserved segment of
this C-terminal third was the TAD. We demonstrated
that this is indeed the case by performing standard,
complementary assays. We ﬁrst proved that this domain
is needed for transactivation by showing that its deletion
abrogates transactivation. We then demonstrated that it is
suﬃcient for transactivation by showing that its fusion to
the GAL4 DNA-binding domain results in a protein
capable of transactivating a GAL4 reporter. Supporting
the notion that the C33 region is solely responsible for
transactivation, we showed that the GAL4/C33 fusions
Figure 7. Dominant-negative interference of SoxC proteins truncated in the C-terminus. (A) Test of the ability of SoxC proteins lacking the C33
domain to interfere with the activity of SoxC full-length proteins. Cos1 cells were transfected with 100ng Brn2 expression plasmid, 100ng SoxC full-
length expression plasmid and 100ng truncated SoxC protein expression plasmid, and with the 6FXO-p89Luc reporter and control plasmids. SoxC
and Brn2 proteins were detected by western blot using an anti-FLAG antibody. (B) Test of the ability of Sox11 proteins lacking various lengths of
the C-terminus to interfere with the activity of full-length Sox11. Cos1 cells were transfected with 100ng Sox11 full-length expression plasmid and
either 20 or 100ng truncated Sox11 expression plasmid, as indicated, and with the 6FXO-p89Luc reporter and control plasmids. The Sox11 proteins
were detected by western blot using an anti-FLAG antibody. (C) Inhibition of the activity of the Tubb3 promoter by SoxC proteins lacking the C33
domain. Cos1 cells were transiently transfected with the Tubb3-pLuc reporter and with 600ng of the expression plasmids for the mutant SoxC
proteins.
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SoxC segment, and that deletion of the region located
directly upstream of C33 had not eﬀect on the ability of
Sox4 and Sox11 to transactivate a Sox reporter. With
only 33 residues, the SoxC TAD is strikingly short, the
shortest mapped in the Sox family (2). It has nevertheless a
typical TAD amino acid composition, with acidic, serine
and proline residues accounting together for almost half of
the residues. Using Prosite and ELM software, we found
that this domain features three putative phosphorylation
sites conserved in all SoxC proteins: a casein kinase-2
phosphorylation site at position S363 in Sox11, a glycogen
synthase kinase-3 and a Polo-like kinase site at position
T371; and a Polo-like kinase site at position T376
(unpublished results). Although mutations mimicking
loss-of-function or gain-of-function of these sites did not
aﬀect the activity of Sox11 in our transient reporter assays
(unpublished results), it remains possible that phosphor-
ylation of these conserved sites contributes to modulating
the activity of the SoxC proteins in response to various
signaling pathways in their natural context. Our observa-
tions that the C33 domain is suﬃcient for transactivation
raise the question of the role of the serine-rich region
preceding the TAD in Sox4 and Sox11. This region was
predicted to participate in transactivation, based on the
fact that TADs are often serine-rich (8,9). Although this
region was not needed for transactivation of GAL4 and
Sox reporters, we cannot exclude the possibility that it
may modulate the activity of the proteins on endogenous
target genes in vivo. It is unlikely, however, that its role is
highly speciﬁc and essential, given that this region greatly
varies in length and sequence across species.
We conﬁrmed that Sox11 is a more potent transacti-
vator than Sox4 (9), and we also demonstrated that Sox12
is a transactivator, but weaker than Sox4 and Sox11.
This conclusion was reached using somewhat artiﬁcial
reporter genes that contained diﬀerent Sox sites, ﬂanking
sequences and Sox site copy numbers, but it was also
reached using the natural Tubb3 promoter, the only
alleged target gene currently known for Sox4 and Sox11
(15). The reproducibility of our results using very diﬀerent
reporters thus strongly suggests that the three proteins
also transactivate their direct target genes in vivo with
diﬀerent eﬃciencies. We then showed that even though
they are highly conserved, the TADs of the SoxC proteins
are responsible at least for a large part for the diﬀerences
in transactivation eﬃciencies between the three proteins.
The fusion of GAL4 with the Sox11 TAD was indeed
more potent than the fusion with the Sox4 or Sox12 TAD.
Moreover, Sox4 and Sox12 were also more active with a
swapped Sox11 TAD than with either of their domains,
and Sox11 was less active with a Sox4 or Sox12 TAD than
with its own domain. Secondary structure models
predicted that 20 residues of the Sox11 TAD form a
continuous a-helix, but that this helix is shorter and
interrupted in both Sox4 and Sox12. The length and
stability of this helix is thus likely to determine the
strength of the SoxC TADs. Interestingly, the secondary
structure of each SoxC TAD is highly conserved between
orthologues, strongly suggesting that each protein has
conserved or acquired unique residues that determine its
speciﬁc activity, and thus that co-expression of the three
genes does not necessarily imply redundancy.
We next demonstrated that the three SoxC proteins
diﬀer not only in their transactivation eﬃciency, but also
in their DNA-binding eﬃciency. We showed that full-
length Sox4 avidly binds DNA in EMSA, as do Sox
proteins from other groups, namely the SoxD Sox6 and
SoxE Sox9, whereas full-length Sox12 binds DNA less
eﬃciently, and full-length Sox11 hardly binds DNA. Our
data on full-length Sox11 are thus consistent with those
published by Wiebe and collaborators (12). This group
reported that they tried to improve binding of Sox11 to
DNA by varying EMSA conditions, but did not succeed.
Similarly, we tested many parameters, including salt and
detergent type and concentration, pH, Sox and other
protein concentration, and diﬀerent nonspeciﬁc DNA
competitors, but also failed (unpublished results). We thus
conclude that a potent mechanism may exist that blocks
binding of Sox11 to DNA. Given that their HMG
box domains are virtually identical, we postulated that
the diﬀerences in DNA-binding eﬃciency between the
three SoxC proteins were due to sequence diﬀerences lying
outside the HMG box. We veriﬁed the accuracy of this
prediction by showing that the three SoxC proteins avidly
and similarly bind DNA when their C-terminal half or
third is deleted. We conﬁrmed the report by Wiebe and
collaborators (12) that deletion of the main acidic stretch
in the middle of Sox11 increases the ability of the protein
to bind DNA. We, however, provided additional data that
signiﬁcantly extend the conclusion reached by this group.
We showed that deleting the other acidic region of the
protein or the C52 domain had a similar eﬀect. Moreover,
deleting the acidic regions of Sox12 also increased the
eﬃciency of DNA binding of the protein. Our data thus
indicated that several regions in Sox11 and Sox12 have the
ability to interfere with binding of the HMG box to DNA
in vitro. They prompted us to test whether the SoxC
proteins also diﬀer in their DNA-binding eﬃciency in
intact cells.
Evidence from our study and previous studies that
Sox11 robustly transactives reporters harboring Sox
recognition sites in transfected cells provides irrefutable
demonstration that Sox11 is capable of binding DNA in
cells. The question then arises of the eﬃciency with which
Sox11 binds DNA compared to Sox4 and Sox12. Our
observation that a plateau of maximum transactivation of
reporter genes is reproducibly obtained with less Sox4 or
Sox12 protein than Sox11 protein is consistent with the
notion that Sox11 does not bind DNA as eﬃciently as
Sox4 and Sox12 in cells. The conﬁrmation of the previous
ﬁnding (12) that Sox11 is a better transactivator in cells
upon deletion of its acidic regions is also consistent with
the notion that the acidic regions reduce the DNA-binding
eﬃciency of Sox11. We obtained a similar result for
Sox12, though, indicating that the two proteins may be
similarly aﬀected. To test the role of the C-terminal
region, which contains the TAD, we tested whether SoxC
proteins lacking the C-terminus were able to interfere with
the activity of SoxC full-length proteins. We found that
Sox11 lacking the C33 domain was capable of interfering
in a dominant-negative manner with the activity of
3114 Nucleic Acids Research, 2008, Vol. 36, No. 9any SoxC full-length protein. Its eﬃciency was similar to
that of Sox4 and Sox12 lacking the same domain. This
result thus suggests that the C33 domain may also reduce
the ability of Sox11 to bind DNA in cells. Interestingly,
truncations of Sox11 in the C-terminal half had similar
eﬀects whether they removed the C33 domain only or also
removed the acidic regions. Among several scenarios that
can be proposed to account for these DNA-binding
inhibitory eﬀects of distinct protein domains, we like to
favor a scenario, whereby these regions would act in
concert with one another. We propose that the acidic
domains might act as hinges to allow the C33 domain to
block access of the HMG box domain to DNA. In this
model, the C33 domain would have the dual function of
mediating transactivation and indirectly restricting its own
activity by limiting binding of the protein to DNA. The
control of SoxC activity in vivo could thus involve factors
capable of preventing negative autoregulation. These
factors could include transcription factors that have
been shown to physically interact and synergize with
the Sox HMG box in binding DNA, such as Brn2 that we
used in this study, but also other POU domain proteins,
homeodomain proteins, basic helix–loop–helix proteins,
and other proteins (46,47). These factors may synergize
with SoxC proteins at least in part by blocking access
of other regions of the SoxC proteins to the
HMG box domain. Other and yet unknown factors
involved in preventing negative autoregulation could
include the transcriptional co-activators that are likely to
interact with the C33 domain, or proteins that may
speciﬁcally interact with the acidic regions of the SoxC
proteins. Identifying SoxC-interacting proteins in future
work using for instance a yeast two-hybrid approach
should help increase understanding of the mode of action
and mode of regulation of these proteins.
Based on the fact that all three SoxC proteins are
transcriptional activators, they can be predicted to
function similarly where co-expressed in vivo. However,
our results suggest that Sox12 may act to temper the
activity of Sox4 and Sox11, by successfully competing
with its group members for DNA binding and thereby
preventing the other two proteins, which have a stronger
TAD, to exert their full activity. The consequences of
inactivating Sox12 in vivo are not known yet. One can now
speculate that inactivation of Sox12 may lead to eﬀects
opposite to those observed upon inactivating Sox4 and
Sox11 in sites of co-expression. On the other hand, the
consequences of inactivating Sox4 and/or Sox11 may be
partially or completely compensated by Sox12. It will thus
be important to compare the consequences of inactivating
the genes individually and simultaneously. Generating
double and triple knockouts for these genes is predicted to
be a laborious and diﬃcult task, as it is for any set of
genes, but most particularly considering that the Sox4 and
Sox11 single knockout mice die early. Another approach
could be to express a SoxC mutant protein capable of
blocking the activity of wild-type SoxC proteins in a
dominant-negative manner.
In this context, our data demonstrating that any of the
three SoxC proteins lacking its C33 domain is capable of
inhibiting transactivation of reporter constructs by any of
the wild-type SoxC proteins is particularly interesting.
These truncated SoxC proteins are likely to act by
competing with the wild-type proteins for DNA binding.
Notably, robust inhibition was seen when equal amounts
of wild-type and mutant protein were expressed in
transfected cells. This result strongly suggests that
spontaneous or targeted mutations of the TAD in only
one SoxC allele could cause a disease more severe than a
complete gene knockout. Although no human disease
or spontaneous mouse mutation has yet been reported
that is due to a SoxC mutation, these considerations,
together with the expression pattern of the three genes
and the already known consequences of inactivating Sox4
and Sox11 in the mouse, strongly suggest that diseases due
to mutations in a SoxC gene could be very severe. Not
only gene mutations could interfere with the activity of
SoxC proteins, but also physiological or pathological
events that could induce protein posttranslational mod-
iﬁcations, such as proteolysis, phosphorylation or
SUMOylation.
In conclusion, this study signiﬁcantly increases our
knowledge of the relative expression pattern and mole-
cular properties of the three SoxC proteins. Sox4 and
Sox11 were previously shown to be essential in several
major developmental, physiological and pathological
processes. Our data strongly suggest that the two genes
are likely to functionally interact with each other as well as
with their close relative Sox12 in many processes, both
positively and negatively, and therefore that the extent to
which they have been thought so far to contribute to
important processes in vivo has probably been largely
underestimated. Their roles in these and other processes
will be fully uncovered only by studying the three genes
simultaneously.
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